Anti-VEGF for AMD a top advancement

Article

San Francisco?Anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration represent the most significant advancement in ophthalmology over the past decade, according to 52% of respondents to an online survey of members of the American Academy of Ophthalmology conducted in December.

San Francisco-Anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration represent the most significant advancement in ophthalmology over the past decade, according to 52% of respondents to an online survey of members of the American Academy of Ophthalmology conducted in December.

The treatment received the highest percentage of votes from the 423 survey participants.

Other noted advancements and the percentages of survey respondents who voted for them:

• Optical coherence tomography (24%).

• Prostamide (prostaglandin-ethanolamide) eye drops for glaucoma (6.6%).

• Premium IOLs, the femtosecond laser, gene therapy for Leber's congenital amaurosis, and Descemet's stripping automated endothelial keratoplasty (about 3% each).

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
A close up of an eye with a brown iris, concept image for diabetic retinopathy and glaucoma research. Image credit: ©Made in Uruguay from Pexels – Canva.com

Perfuse Therapeutics shares findings from glaucoma and diabetic retinopathy trials of PER-001

Sydney M Crago
July 9th 2025
Article

Phil Lai, MD, chief medical officer of Perfuse Therapeutics, said the company's goal is to pioneer disease-modifying treatment that targets an underlying pathology of ischemia

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
Nationwide free transport for cataract patients through SpaMedica

Nationwide free transport for cataract patients through SpaMedica

Lynda Charters
July 8th 2025
Article

SpaMedica to offer free transport for all NHS cataract patients, supporting community care and reducing health inequalities.

A photo showing Sebastian Rausch, PhD, clinical development manager for investigational technologies (left) and Roland Rocholz, PhD, technology and innovation manager. Image courtesy of Heidelberg Engineering

Heidelberg Engineering launches ZinserLab innovation hub, expands Orbis collaboration

Jordana Joy
July 7th 2025
Article

The imaging innovation project is named after the company's cofounder Gerhard Zinser, PhD

The International Space Station (ISS) pictured in orbit above Earth. Concept image for International Spectralis Symposium conference meeting in Heidelberg, Germany, and NASA. ©Paopano – stock.adobe.com

Long-duration spaceflight tests the limits of telemedicine

Sheryl Stevenson;Steven Laurie, PhD
July 3rd 2025
Article

In-orbit imaging drives innovation in terrestrial telemedicine, the NASA scientist explained

A group of older elderly people exercise outdoors. Concept image for dry eye disease and aging, demographics of Tear Film and Ocular Surface Society TFOS DEWS III Digest report. Image credit: ©Rido – stock.adobe.com

Interdisciplinary report illuminates demographic, systemic health factors of dry eye disease

Jordana Joy
July 2nd 2025
Article

Remaining questions about DED pertain to geographic considerations, prevalence measures for DED in children and the design of future studies to determine risk factors in patients under 40

© 2025 MJH Life Sciences

All rights reserved.